Sou Hu Cai Jing·2026-03-16 14:52Group 1 - The core point of the article is that Zhaoyan New Drug (603127) has disclosed a significant investment in financial products amounting to RMB 460 million, which is expected to yield annual returns between 1.5% and 5.15% [1] - As of March 16, 2026, Zhaoyan New Drug's stock closed at 32.58 yuan, with a market capitalization of 24.414 billion yuan, reflecting a 0.52% increase from the previous trading day [1] - The company confirmed that the investment in financial products will not adversely affect its financial status, as previous investments have been fully redeemed [1] Group 2 - The financial products involved include collective asset management plans and single asset management plans, with investment amounts ranging from RMB 10 million to 180 million [1] - The trading activity constitutes a disclosure transaction as the percentage of the combined calculation is above 5% but below 25%, necessitating compliance with listing rules [1]